GeneDx Holdings Corp.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| WGS | MYGN | NEO | PSNL | BDSX | BLLN | |
|---|---|---|---|---|---|---|
| Market cap | 2.07B | 575.81M | 2.22B | 1.69B | 226.74M | 5.37B |
| P/E (TTM) | — | — | — | — | — | 180.8 |
| Forward P/E | 57.9 | -10.2 | 54.5 | -16.3 | -97.7 | 76.7 |
| Price/book | 8.5 | 1.9 | 2.8 | 6.2 | 24.8 | 9.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −49.85% | −8.21% | +61.36% | +105.61% | +144.77% | +1.39% |
| Today | +1.02% | −0.33% | +1.90% | +0.25% | +2.09% | +3.11% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All WGS news ›GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
GAITHERSBURG, Md.--(BUSINESS WIRE)--Jan. 12, 2026-- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full…
GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
ultraRapid testing addresses the underutilization of testing in the NICU and can lead to more than $15K in healthcare savings per child GAITHERSBURG, Md.--(BUSINESS WIRE)--Feb. 13, 2025-- GeneDx (Nasdaq: WGS), a leader in delivering…
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
BioSpace GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis GeneDx combines clinical expertise with a phenotype-driven approach to solve compl
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
Research strengthens the evidence for exome and genome sequencing as standard of care across rare disease, autism, newborn screening and beyond GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving…
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
GUARDIAN findings show genomic and standard newborn screening identified cases the other approach missed. Data from BRIDGES-NBS shows an expert-informed approach to broadening the number of actionable conditions appropriate for gNBS New…
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DXC Technology Company (DXC) And Encourages Shareholders to Reach Out
ACCESS Newswire provides PR agencies with trusted press release distribution, media outreach tools, media lists, pitching features, analytics, monitoring, and dedicated support designed for multi-client workflows. Bronstein, Gewirtz &…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- ir.genedx.com2
- accessnewswire.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.